{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:22:23Z","timestamp":1777432943798,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005676","name":"Fundaci\u00f3n Josep Carreras Contra la Leucemia","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005676","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Obra Social La Caixa","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12967-016-1007-5","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T13:01:45Z","timestamp":1473253305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Repositioning of bromocriptine for treatment of acute myeloid leukemia"],"prefix":"10.1186","volume":"14","author":[{"given":"Mar\u00eda Carmen","family":"Lara-Castillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Maria","family":"Cornet-Masana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaia","family":"Etxabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f2nia","family":"Ban\u00fas-Mulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Torrente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Nomdedeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-9536","authenticated-orcid":false,"given":"Ruth M.","family":"Risue\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"1007_CR1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","volume":"381","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484\u201395.","journal-title":"Lancet"},{"key":"1007_CR2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","volume":"34","author":"N Novac","year":"2013","unstructured":"Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34:267\u201372.","journal-title":"Trends Pharmacol Sci"},{"key":"1007_CR3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730\u20137.","journal-title":"Nat Med"},{"key":"1007_CR4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086\u201393.","journal-title":"Nat Med"},{"key":"1007_CR5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MOH.0b013e3283257aee","volume":"16","author":"K Petrie","year":"2009","unstructured":"Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol. 2009;16:84\u201391.","journal-title":"Curr Opin Hematol"},{"key":"1007_CR6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315\u201321.","journal-title":"Nat Biotechnol"},{"key":"1007_CR7","doi-asserted-by":"crossref","first-page":"21131","DOI":"10.3402\/jmahp.v1i0.21131","volume":"1","author":"S Murteira","year":"2013","unstructured":"Murteira S, Ghezaiel Z, Karray S, Lamure M. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. J Mark Access Health Policy. 2013;1:21131.","journal-title":"J Mark Access Health Policy"},{"key":"1007_CR8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303:791\u2013804.","journal-title":"J Pharmacol Exp Ther"},{"key":"1007_CR9","first-page":"417","volume":"268","author":"SB Freedman","year":"1994","unstructured":"Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994;268:417\u201326.","journal-title":"J Pharmacol Exp Ther"},{"key":"1007_CR10","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.18632\/oncotarget.2016","volume":"5","author":"D Moreno-Martinez","year":"2014","unstructured":"Moreno-Martinez D, Nomdedeu M, Lara-Castillo MC, Etxabe A, Pratcorona M, Tesi N, Diaz-Beya M, Rozman M, Montserrat E, Urbano-Ispizua A, et al. XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Oncotarget. 2014;5:4337\u201346.","journal-title":"Oncotarget"},{"key":"1007_CR11","doi-asserted-by":"crossref","first-page":"23239","DOI":"10.18632\/oncotarget.8096","volume":"7","author":"JM Cornet-Masana","year":"2016","unstructured":"Cornet-Masana JM, Moreno-Martinez D, Lara-Castillo MC, Nomdedeu M, Etxabe A, Tesi N, Pratcorona M, Esteve J, Risueno RM. Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. Oncotarget. 2016;7:23239\u201350.","journal-title":"Oncotarget"},{"key":"1007_CR12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929\u201335.","journal-title":"Science"},{"key":"1007_CR13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V54.3.713.713","volume":"54","author":"R Gallagher","year":"1979","unstructured":"Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54:713\u201333.","journal-title":"Blood"},{"key":"1007_CR14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1126\/science.306682","volume":"200","author":"HP Koeffler","year":"1978","unstructured":"Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science. 1978;200:1153\u20134.","journal-title":"Science"},{"key":"1007_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0145-2126(96)00129-4","volume":"21","author":"KG Steube","year":"1997","unstructured":"Steube KG, Teepe D, Meyer C, Zaborski M, Drexler HG. A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. Leuk Res. 1997;21:327\u201335.","journal-title":"Leuk Res"},{"key":"1007_CR16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V77.9.2031.2031","volume":"77","author":"H Asou","year":"1991","unstructured":"Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77:2031\u20136.","journal-title":"Blood"},{"key":"1007_CR17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"1007_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20008","volume":"60","author":"EG Lochem van","year":"2004","unstructured":"van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004;60:1\u201313.","journal-title":"Cytometry B Clin Cytom"},{"key":"1007_CR19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0140-6736(74)92219-3","volume":"2","author":"DB Calne","year":"1974","unstructured":"Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of parkinsonism with bromocriptine. Lancet. 1974;2:1355\u20136.","journal-title":"Lancet"},{"key":"1007_CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.1.5953.299","volume":"1","author":"MO Thorner","year":"1975","unstructured":"Thorner MO, Chait A, Aitken M, Benker G, Bloom SR, Mortimer CH, Sanders P, Mason AS, Besser GM. Bromocriptine treatment of acromegaly. Br Med J. 1975;1:299\u2013303.","journal-title":"Br Med J"},{"key":"1007_CR21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.2.5916.419","volume":"2","author":"MO Thorner","year":"1974","unstructured":"Thorner MO, McNeilly AS, Hagan C, Besser GM. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J. 1974;2:419\u201322.","journal-title":"Br Med J"},{"key":"1007_CR22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF01930467","volume":"48","author":"AH Meier","year":"1992","unstructured":"Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia. 1992;48:248\u201353.","journal-title":"Experientia"},{"key":"1007_CR23","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2009.175","volume":"23","author":"F Ayala","year":"2009","unstructured":"Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009;23:2233\u201341.","journal-title":"Leukemia"},{"key":"1007_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","volume":"18","author":"K Mrozek","year":"2004","unstructured":"Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115\u201336.","journal-title":"Blood Rev"},{"key":"1007_CR25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discovery. 2004;3:673\u201383.","journal-title":"Nat Rev Drug Discovery"},{"key":"1007_CR26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","volume":"23","author":"H Pijl","year":"2000","unstructured":"Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154\u201361.","journal-title":"Diabetes Care"},{"key":"1007_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/DMSO.S9575","volume":"3","author":"MA Via","year":"2010","unstructured":"Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diab Metab Syndr Obes Targets Therapy. 2010;3:43\u20138.","journal-title":"Diab Metab Syndr Obes Targets Therapy"},{"key":"1007_CR28","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/ci400284v","volume":"53","author":"CL Bellera","year":"2013","unstructured":"Bellera CL, Balcazar DE, Alberca L, Labriola CA, Talevi A, Carrillo C. Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects. J Chem Inf Model. 2013;53:2402\u20138.","journal-title":"J Chem Inf Model"},{"key":"1007_CR29","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","volume":"149","author":"E Sachlos","year":"2012","unstructured":"Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee J-H, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149:1284\u201397.","journal-title":"Cell"},{"issue":"6","key":"1007_CR30","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.18632\/oncotarget.6773","volume":"7","author":"FG Liberante","year":"2016","unstructured":"Liberante FG, Pouryahya T, McMullin MF, Zhang SD, Mills KI. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget. 2016;7(6):6609\u201319.","journal-title":"Oncotarget"},{"key":"1007_CR31","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1007_CR32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07853890.2015.1009156","volume":"47","author":"C Dan","year":"2015","unstructured":"Dan C, Chi J, Wang L. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy. Ann Med. 2015;47:209\u201317.","journal-title":"Ann Med"},{"key":"1007_CR33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ajh.23211","volume":"87","author":"R Devillier","year":"2012","unstructured":"Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol. 2012;87:659\u201362.","journal-title":"Am J Hematol"},{"key":"1007_CR34","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1002\/ajh.23850","volume":"90","author":"R Devillier","year":"2015","unstructured":"Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D\u2019Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. Am J Hematol. 2015;90:E22\u20134.","journal-title":"Am J Hematol"},{"key":"1007_CR35","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ajh.23772","volume":"89","author":"XQ Xu","year":"2014","unstructured":"Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, Hu XX, Yang JM, Ni X, Chen J, et al. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: a retrospective analysis in a cohort of Chinese patients. Am J Hematol. 2014;89:874\u201381.","journal-title":"Am J Hematol"},{"key":"1007_CR36","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","volume":"113","author":"OK Weinberg","year":"2009","unstructured":"Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113:1906\u20138.","journal-title":"Blood"},{"key":"1007_CR37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1309\/EM7KCQR4GLMHRCX4","volume":"119","author":"DA Arber","year":"2003","unstructured":"Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672\u201380.","journal-title":"Am J Clin Pathol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-1007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T20:48:54Z","timestamp":1601066934000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-016-1007-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/s12967-016-1007-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"article-number":"261"}}